<table class="drug-table data-table table table-condensed table-bordered"><tbody><tr id="identification"><th class="divider" colspan="2">Identification</th></tr><tr><th>Name</th><td><strong>Regadenoson</strong></td></tr><tr><th>Accession Number</th><td><strong>DB06213</strong></td></tr><tr><th>Type</th><td>small molecule</td></tr><tr><th>Groups</th><td>approved</td></tr><tr><th>Description</th><td><p>Regadenoson is an A2A adenosine receptor agonist that causes coronary vasodilation and used for myocardial perfusion imagining. Manufactured by Astellas and <span class="caps">FDA</span> approved April 10, 2008.</p></td></tr><tr><th>Structure</th><td><div class="structure"><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DB06213/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DB06213/thumb.png"></a></div><div class="structure-links"><div class="btn-group btn-group-xs"><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB06213.mol">MOL</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB06213.sdf">SDF</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB06213.pdb">PDB</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB06213.smiles">SMILES</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB06213.inchi">InChI</a><a class="btn btn-info" href="/structures/structures/small_molecule_drugs/DB06213">View Structure</a></div></div></td></tr><tr><th>Synonyms</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Salts</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Brand names</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="brands"><thead><tr><th>Name</th><th>Company</th></tr></thead><tbody><tr><td>Lexiscan</td><td>Astellas Pharma US, Inc</td></tr></tbody></table></td></tr><tr><th>Brand mixtures</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Categories</th><td><ul><li><a href="/mesh/diagnostic-agents">Diagnostic Agents</a></li></ul></td></tr><tr><th>CAS number</th><td>313348-27-5</td></tr><tr><th>Weight</th><td>Average: 390.354<br>Monoisotopic: 390.140015726</td></tr><tr><th>Chemical Formula</th><td>C<sub>15</sub>H<sub>18</sub>N<sub>8</sub>O<sub>5</sub></td></tr><tr><th>InChI Key</th><td>LZPZPHGJDAGEJZ-AKAIJSEGSA-N</td></tr><tr><th>InChI</th><td><div class="wrap">InChI=1S/C15H18N8O5/c1-17-13(27)6-2-19-23(3-6)15-20-11(16)8-12(21-15)22(5-18-8)14-10(26)9(25)7(4-24)28-14/h2-3,5,7,9-10,14,24-26H,4H2,1H3,(H,17,27)(H2,16,20,21)/t7-,9-,10-,14-/m1/s1</div></td></tr><tr><th>IUPAC Name</th><td><div class="wrap">1-{6-amino-9-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-9H-purin-2-yl}-N-methyl-1H-pyrazole-4-carboxamide</div></td></tr><tr><th>SMILES</th><td><div class="wrap">CNC(=O)C1=CN(N=C1)C1=NC2=C(N=CN2[C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)C(N)=N1</div></td></tr><tr><th>Mass Spec</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="taxonomy"><th class="divider" colspan="2">Taxonomy</th></tr><tr><th>Kingdom</th><td>Organic Compounds</td></tr><tr><th>Superclass</th><td>Organooxygen Compounds</td></tr><tr><th>Class</th><td>Carbohydrates and Carbohydrate Conjugates</td></tr><tr><th>Subclass</th><td>Glycosyl Compounds</td></tr><tr><th>Direct parent</th><td>Purine Nucleosides and Analogues</td></tr><tr><th>Alternative parents</th><td>Pentoses; Purines and Purine Derivatives; Aminopyrimidines and Derivatives; N-substituted Imidazoles; Primary Aromatic Amines; Tetrahydrofurans; Pyrazoles; Oxolanes; Secondary Carboxylic Acid Amides; Secondary Alcohols; 1,2-Diols; Ethers; Enolates; Carboxylic Acids; Primary Alcohols; Polyamines</td></tr><tr><th>Substituents</th><td>pentose monosaccharide; imidazopyrimidine; purine; aminopyrimidine; pyrimidine; primary aromatic amine; monosaccharide; n-substituted imidazole; tetrahydrofuran; pyrazole; oxolane; imidazole; azole; secondary carboxylic acid amide; carboxamide group; secondary alcohol; 1,2-diol; primary alcohol; polyamine; carboxylic acid derivative; enolate; carboxylic acid; ether; primary amine; organonitrogen compound; alcohol; amine</td></tr><tr><th>Classification description</th><td>This compound belongs to the purine nucleosides and analogues. These are compounds comprising a purine base attached to a sugar.</td></tr><tr id="pharmacology"><th class="divider" colspan="2">Pharmacology</th></tr><tr><th>Indication</th><td>Diagnostic agent for radionuclide myocardial perfusion imaging (MPI) </td></tr><tr><th>Pharmacodynamics</th><td>Regadenoson rapidly increases coronary blood flow (CBF) which is sustained for a short duration. Mean average peak velocity increased to greater than twice baseline by 30 seconds and decreased to less than twice the baseline level within 10 minutes. Myocardial uptake of the radiopharmaceutical is proportional to (CBF). Regadenoson increases blood flow in normal coronary arteries but not in stenotic (blocked) arteries. The significance of this finding is that stenotic arteries will take up less of the radiopharmaceutical than normal coronary arteries, resulting in a signal that is less intense in these areas. </td></tr><tr><th>Mechanism of action</th><td>Regadenoson is an selective low-affinity (Ki= 1.3 &#181;M) A2A receptor agonist that mimics the effects of adenosine in causing coronary vasodilatation and increasing myocardial blood flow. It is a very weak agonist of the A1 adenosine receptor (Ki &gt; 16.5 &#181;M). Furthermore, it has negligible affinity to A2B and A3 adenosine receptors. Regadenoson is undergoing trials for use in pharmacological stress tests. Adenosine slows conduction time through the A-V node, can interrupt the reentry pathways through the A-V node, and can restore normal sinus rhythm in patients with paroxysmal supraventricular tachycardia (PSVT), including PSVT associated with Wolff-Parkinson-White Syndrome.</td></tr><tr><th>Absorption</th><td>The pharmacokinetic profile of regadenoson is best described by a 3-compartment model. 
T max, injection = 1 to 3 minutes;
Onset of pharmacodynamic response = 1 to 3 minutes;  
E max 12.3 ng/mL 
</td></tr><tr><th>Volume of distribution</th><td><p>Central compartment: 11.5 L;<br>
Steady state: 78.7 L</p></td></tr><tr><th>Protein binding</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Metabolism</th><td class="data-table-container"><p>The metabolism of regadenoson is unknown in humans. The cytochrome P450 enzyme system is not likely to be involved with the metabolism of regadenoson. </p></td></tr><tr><th>Route of elimination</th><td>58% of total regadenoson eliminate is via renal excretion </td></tr><tr><th>Half life</th><td>Initial phase: 2-4 minutes;
Intermediate phase: 30 minutes (this phase coincides with a loss of the pharmacodynamic effect); 
Terminal phase: 2 hours </td></tr><tr><th>Clearance</th><td><p>Average plasma renal clearance = 450 mL/min. As this value is larger than the glomerular filtration rate, this suggests occurrence of renal tubular secretion.</p></td></tr><tr><th>Toxicity</th><td>The most common (incidence &#8805; 5%) adverse reactions to regadenoson are dyspnea, headache, flushing, chest discomfort, dizziness, angina pectoris, chest pain, and nausea. 
MTD (male, supine position): 20 &#181;g/kg; 
MTD (male, standing position): 10 &#181;g/kg;</td></tr><tr><th>Affected organisms</th><td><ul><li>Humans and other mammals</li></ul></td></tr><tr><th>Pathways</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Effects</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Adverse Drug Reactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="admet"><th class="divider" colspan="2">ADMET</th></tr><tr><th>Predicted ADMET features</th><td class="data-table-container"><table class="table table-condensed table-striped" id="predicted-admet">
  <thead>
    <tr>
      <th>Property</th>
      <th>Value</th>
      <th>Probability</th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>Human Intestinal Absorption</td>
        <td>
              +
        </td>
        <td>1.0</td>
      </tr>
      <tr>
        <td>Blood Brain Barrier</td>
        <td>
              +
        </td>
        <td>0.7551</td>
      </tr>
      <tr>
        <td>Caco-2 permeable</td>
        <td>
              -
        </td>
        <td>0.7753</td>
      </tr>
      <tr>
        <td>P-glycoprotein substrate</td>
        <td>
            Non-substrate
        </td>
        <td>0.6036</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor I</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.9328</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor II</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.9762</td>
      </tr>
      <tr>
        <td>Renal organic cation transporter</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.9423</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-substrate</td>
        <td>0.8795</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-substrate</td>
        <td>0.8433</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Substrate</td>
        <td>0.5052</td>
      </tr>
      <tr>
        <td>CYP450 1A2 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.8108</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9275</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9568</td>
      </tr>
      <tr>
        <td>CYP450 2C19 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9373</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9626</td>
      </tr>
      <tr>
        <td>CYP450 inhibitory promiscuity</td>
        <td>Low CYP Inhibitory Promiscuity</td>
        <td>0.9931</td>
      </tr>
      <tr>
        <td>Ames test</td>
        <td>
          Non AMES toxic 
        </td>
        <td>
            0.6997
        </td>
      </tr>
      <tr>
        <td>Carcinogenicity</td>
        <td>
          Non-carcinogens 
        </td>
        <td>
            0.8987
        </td>
      </tr>
      <tr>
        <td>Biodegradation</td>
        <td>
          Not ready biodegradable 
        </td>
        <td>
            0.9669
        </td>
      </tr>
      <tr>
        <td>Rat acute toxicity</td>
        <td>
          2.2022 
            LD50, mol/kg
        </td>
        <td>
            <span class="wishart wishart-not-available">Not applicable</span>
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor I)</td>
        <td>
          Weak inhibitor 
        </td>
        <td>
            0.964
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor II)</td>
        <td>
          Non-inhibitor 
        </td>
        <td>
            0.8999
        </td>
      </tr>
  </tbody>
</table>
</td></tr><tr id="pharmacoeconomics"><th class="divider" colspan="2">Pharmacoeconomics</th></tr><tr><th>Manufacturers</th><td><ul><li>Astellas pharma us inc</li></ul></td></tr><tr><th>Packagers</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Dosage forms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="dosages"><thead><tr><th>Form</th><th>Route</th><th>Strength</th></tr></thead><tbody><tr><td>Solution</td><td>Intravenous</td><td>0.4mg/5 mL </td></tr></tbody></table></td></tr><tr id="spectra"><th class="divider" colspan="2">Spectra</th></tr><tr><th>Spectra</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="interactions"><th class="divider" colspan="2">Interactions</th></tr><tr><th>Drug Interactions</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Drug</th><th style="width: 75%"></th></tr></thead><tbody><tr><td><a href="/drugs/DB01223">Aminophylline</a></td><td>Reduces duration of &gt;2-fold increase in peak flow velocity. No effect on heart rate increase.</td></tr><tr><td><a href="/drugs/DB00201">Caffeine</a></td><td>Caffeine may diminish the vasodilatory effect of Regadenoson. Regadenoson prescribing information recommends avoiding using caffeine or other methylxanthine containing products (e.g., theophylline) for at least 12 hours prior the the administration of regadenoson. The impact of low doses of caffeine-containing products such as coffee, tea, and colas is unclear. </td></tr><tr><td><a href="/drugs/DB00975">Dipyridamole</a></td><td>Dipyridamole may change the effects of regadenoson. When possible, withhold dipyridamole for at least two days prior to regadenoson administration. </td></tr><tr><td><a href="/drugs/DB00277">Theophylline</a></td><td>Non-specific adenosine receptor antagonist may interfere with the vasodilation activity of regadenoson. Avoid methylxanthines for at least 12 hours before administration of regadenoson. </td></tr></tbody></table></td></tr><tr><th>Food Interactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table>